Ozempic will drop the scale. That part is real. What the prescription doesn't come with is a warning that roughly a third of what you lose won't be fat.
The STEP 1 trial — the landmark study that put semaglutide on the map — enrolled 1,961 adults, ran 68 weeks, and produced a mean weight loss of 14.9% in the treatment group. Impressive. But buried in the supplementary data is the body composition breakdown from the DXA subpopulation: total lean body mass decreased alongside fat mass. The drug doesn't distinguish. When you're in a significant caloric deficit driven by appetite suppression, your body pulls from everything available — and without deliberate resistance training and protein intake, a substantial portion of what's lost is muscle.
TL;DR: STEP 1 trial (N=1,961, 68 weeks) showed 14.9% mean weight loss on semaglutide. Without resistance training, research consistently shows ~25-39% of weight lost during aggressive caloric restriction comes from lean mass. A 15kg loss becomes 4-6kg of muscle gone. The drug works. The protocol around it is what most people are missing.
The number everyone quotes and the one they don't
The headline from STEP 1: -14.9% body weight versus -2.4% on placebo. That's a real, meaningful difference — 86.4% of semaglutide participants lost at least 5% of their body weight compared to 31.5% on placebo. The drug works as an appetite suppressor.
But weight loss and fat loss aren't the same thing.
A 90kg person who loses 13.5kg on semaglutide without a structured resistance program doesn't lose 13.5kg of fat. Based on body composition data from multiple GLP-1 trials and caloric-restriction studies, somewhere between 25-39% of that loss is lean mass. That's 3.4-5.3kg of muscle, gone.
Run the numbers differently. If that same person loses 15kg total and 5kg is lean mass, their fat-free mass drops from roughly 65kg to 60kg. Their metabolic rate drops with it. Their strength drops with it. And when the medication stops — which it eventually does, either by choice or by cost — weight regain without that muscle base is faster and harder to reverse.
This isn't a reason not to use GLP-1 drugs. It's a reason to use them correctly.
Why GLP-1 drugs cause muscle loss
Semaglutide works by mimicking GLP-1, a gut hormone that signals satiety. You eat less. Your body enters a significant caloric deficit — the STEP 1 protocol targeted a 500 kcal/day deficit on top of the pharmacological suppression.
Under aggressive caloric restriction, the body does something predictable: it breaks down protein for energy. Without mechanical stress on the muscle — resistance training that signals your body to preserve it — muscle becomes a fuel source. The more extreme the deficit, the faster this happens.
It's not specific to semaglutide. It's specific to aggressive caloric deficits without resistance training. GLP-1 drugs just make those deficits much easier to sustain, which is why the muscle loss concern is more clinically relevant now than it was when the only way to achieve comparable deficits was through sheer willpower.
The second mechanism: protein intake typically drops when appetite drops. People on GLP-1 drugs often eat significantly less — including less protein. Protein synthesis requires a substrate. If you're eating 80g of protein per day on a GLP-1 drug because you're not hungry, your body can't build or maintain muscle regardless of what your training looks like.
What the research actually recommends
The evidence base here has been building for several years. Multiple systematic reviews and expert consensus papers on GLP-1 use now include resistance training and protein targets as non-negotiable components of any pharmacological weight loss protocol.
The protein target: 1.6-2.2g per kilogram of bodyweight per day, maintained even when appetite is suppressed. This is deliberately above general recommendations because of the muscle-preservation challenge during aggressive deficit.
The training target: 2-3 sessions of progressive resistance training per week, minimum. Not cardio. Not walking 150 minutes per week (which the STEP 1 lifestyle intervention included). Resistance training with progressive overload — the specific mechanical stimulus that tells your body muscle is worth keeping.
With both in place, research on GLP-1 drugs combined with resistance training shows the lean mass loss can be substantially attenuated. The scale goes down. And a much higher proportion of what's lost is actually fat.
What we track
This is the gap between the GLP-1 marketing and the reality that shows up in a proper body composition assessment.
Body weight is a terrible metric for evaluating the quality of weight loss. The scale tells you nothing about where the loss is coming from. InBody 770 scans do — segmental lean mass, body fat percentage, visceral fat, skeletal muscle mass broken out by limb. Bi-weekly scanning shows exactly what's changing and in which direction.
The clients we work with who are on GLP-1 drugs get this tracked from day one. If lean mass is declining faster than fat, the protocol adjusts — protein targets tighten, training intensity increases, and we have an actual number to work against rather than a guess.
The fat-free mass index (FFMI) is the more useful long-term marker. It accounts for height and gives you a standardised view of how much lean mass you carry relative to your frame. That number should be stable or rising during a well-executed weight loss phase. If it's falling, something in the protocol is wrong.
The honest version of the Ozempic conversation
GLP-1 drugs are a genuine advance in obesity pharmacology. The weight loss they produce is real, clinically meaningful, and more sustained than most prior interventions. The STEP 1 data is not hype.
But the prescription alone isn't a body recomposition strategy. Dropping 15kg while losing 5kg of muscle doesn't leave you at your goal weight with a leaner physique — it leaves you lighter, weaker, and with a slower metabolism than you started with. That's the outcome most people on GLP-1 drugs are heading toward without a structured resistance protocol.
The protocol is the intervention. The drug is one component of it.
Common questions
Will I definitely lose muscle on Ozempic? Not inevitably. The research shows lean mass loss is common during aggressive caloric restriction without resistance training — roughly 25-39% of weight lost. With structured resistance training and adequate protein (1.6-2.2g/kg/day), lean mass can be substantially preserved. The drug alone won't cause muscle loss; the deficit it enables, without the right training response, will.
What protein target should I hit on a GLP-1 drug? 1.6-2.2g per kilogram of bodyweight per day, held even when you're not hungry. If you weigh 80kg, that's 128-176g of protein daily. On a GLP-1 drug with suppressed appetite, hitting that number requires deliberate planning — not eating to hunger. This is one of the more underrated parts of the protocol.
How do I know if I'm losing muscle vs fat? You need a body composition assessment, not a scale. InBody 770 scanning gives you segmental lean mass, body fat percentage, and skeletal muscle mass. Bi-weekly tracking shows the trend. A declining FFMI (fat-free mass index) is the signal that your protocol needs adjustment.
What kind of training works best alongside a GLP-1 drug? Progressive resistance training — 2-3 sessions per week with progressively increasing load. The mechanical stimulus from resistance training is what signals your body to preserve muscle during a deficit. Walking, yoga, and general activity are valuable but won't substitute for the anabolic signal that resistance training provides.
When should I start resistance training if I'm on a GLP-1 drug? Day one. Not after you've lost some weight. Not once you feel ready. The muscle preservation benefit is greatest when training is concurrent with the weight loss phase — starting before significant lean mass has been lost is substantially easier than trying to rebuild it afterward.
Study referenced: Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183. N=1,961, 68-week randomised double-blind placebo-controlled trial, 16 countries.
Body composition data: lean mass loss rates during caloric restriction from Cava E, et al. Preserving Healthy Muscle during Weight Loss. Advances in Nutrition. 2017;8(3):511-519. And Jensen MD, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.
